• If you are wondering whether Kenvue stock is starting to look interesting at today’s price, the key question is how that price compares with a fair value estimate.
• The shares last closed at US$17.11, with returns down 2.7% over the past week, down 1.1% over the past month, down 1.2% year to date, and down 26.0% over the past year.
• Recent coverage has focused on how investors are reassessing consumer staples stocks, which can shift attention to balance sheet strength, cash generation and product resilience. For Kenvue, this backdrop helps frame whether the recent share price performance reflects sentiment, fundamentals, or a mix of both.
• On Simply Wall St’s 6 point valuation check, Kenvue scores 3 out of 6. The rest of this article will break down what that means across different valuation methods, and then look at a more complete way to think about value at the end.

Approach 1: Kenvue Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock might be worth by projecting the company’s future cash flows and discounting them back to today’s value. It is essentially asking what the stream of future cash the business could generate is worth in dollars right now.

For Kenvue, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $1.77b. Analysts provide detailed free cash flow estimates for several years ahead and, beyond that point, Simply Wall St extrapolates those forecasts. In this case, the ten year projection shows free cash flow figures moving to $3.30b by 2035, with a specific projection of $2.83b in 2030 and corresponding discounted values that range from about $2.03b in 2026 to $1.57b in 2035.

When all those discounted cash flows are added together, the resulting intrinsic value estimate is $29.89 per share. Compared with the recent share price of $17.11, the DCF implies that Kenvue stock trades at about a 42.8% discount, which screens as materially undervalued on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Kenvue is undervalued by 42.8%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Kenvue Price vs Earnings

For a profitable company, the P/E ratio is a useful way to think about what you are paying for each dollar of current earnings. It is a quick shorthand that many investors use alongside cash flow based methods like the DCF you saw above.

What counts as a “normal” or “fair” P/E depends on how fast earnings are expected to grow and how risky those earnings are perceived to be. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk can point to a lower one.

Kenvue currently trades on a P/E of 20.25x. That sits above the Personal Products industry average P/E of about 19.25x and above the peer group average of 15.26x. Simply Wall St’s Fair Ratio for Kenvue is 20.44x, which is its proprietary estimate of what Kenvue’s P/E might be given factors such as earnings growth, industry, profit margins, market cap and company specific risks.

The Fair Ratio offers a more tailored yardstick than simple peer or industry comparisons because it adjusts for these company specific characteristics. Kenvue’s actual P/E of 20.25x is very close to the Fair Ratio of 20.44x, which indicates that, on this metric, the stock is priced at about fair value.

Result: ABOUT RIGHT

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Kenvue Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to attach a story about Kenvue to your own numbers, link that story to a revenue, earnings and margin forecast, and then see a fair value that you can compare with today’s price to decide whether the stock looks attractive or stretched.

On Simply Wall St’s Community page, Narratives are easy to use, available to millions of investors, and update automatically when new information like news, lawsuits, leadership changes or earnings arrives. This means your fair value view moves with the company rather than staying frozen at the date you built a spreadsheet.

For Kenvue, one investor might build a more optimistic Narrative that leans on factors like aging demographics, premium health products and digital marketing, and reach a fair value closer to US$25.09. Another might focus more on risks such as rising input costs, competition in personalized health, talc related litigation or questions around execution, and settle on a fair value around US$19.58. This illustrates how the same stock can reasonably support very different conclusions depending on which story you find more convincing.

Do you think there's more to the story for Kenvue? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.